Amar Patel, MD
Foot and Ankle Surgery · Lees Summit, MONPI 1841300571
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $170,287 of the $202,844 with a category attached, or 83.9%. Stryker accounts for 83.5% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $62,271, 2.2 times the $27,693 reported in 2019. Among foot and ankle surgery clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 198 payments — averaging $1024.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$169K
- Smith+Nephew$14K
- Arthrex$3K
- Titan Surgical Group, LLC$3K
- Linvatec Corporation$3K
- Osteomed LLC$3K
- plus $7K from 18 others
Across 6 payments — averaging $8916.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Smith+Nephew$54K
Across 9 payments — averaging $1709.26 each. An ownership or investment interest held by the physician or an immediate family member.
- Spinal Simplicity, LLC$15K
- Paragon 28, Inc.$0
What the payments were for
- Royalty or licence$170,28784%
- Consulting fees$20,08810%
- Speaking & faculty fees$1,2501%
- Travel & lodging$6,0323%
- Food & beverage$3,9872%
- Education$1,2001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker(2 entities) | 104 | $169,294 |
| Smith+Nephew | 21 | $14,011 |
| Arthrex | 8 | $3,438 |
| Titan Surgical Group, LLC | 17 | $3,257 |
| Linvatec Corporation | 7 | $3,118 |
| Osteomed LLC | 3 | $2,875 |
| Acumed LLC | 12 | $2,707 |
| In2bones USA, LLC | 2 | $1,091 |
| International Life Sciences | 1 | $1,000 |
| KCI USA, Inc. | 1 | $800 |
| Bone Support Inc. | 2 | $700 |
| Polynovo North America LLC | 4 | $116 |
| Zimmer Biomet | 2 | $99 |
| Heron Therapeutics, Inc. | 1 | $57 |
| Theramicro, Inc. | 1 | $56 |
| Johnson & Johnson(2 entities) | 2 | $50 |
| Ferring Pharmaceuticals Inc. | 2 | $36 |
| Bioventus LLC | 1 | $27 |
| Dynasplint Systems Inc. | 2 | $25 |
| Ossio Inc | 1 | $22 |
| Vertex | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Integra Lifesciences Corporation | 1 | $14 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORTHOLOC 3DI CROSSCHECK$118,387
- CROSSCHECK$49,243
- BioBrace 23mm$2,994
- HERCULES SUTURE ANCHOR SYSTEM$2,775
- OsteoMed$2,517
- EXT-ExtremiLock Ankle$1,750
- CoLink$1,000
- FLEXBAND$1,000
- PREVENA$800
- CERAMENTBONE VOID FILLER$700
- EXT-Cannulated$625
- EXT-Other$500
- Q-FIX$325
- Bone Anchors with Arthroscopic Delivery System$105
How this compares
$202,844 in reported general payments places this provider in the 95th percentile of 163 foot and ankle surgery providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 16 | $8,517 |
| Gabapentin | 211 | $2,697 |
| Pregabalin | 69 | $1,421 |
| Enoxaparin Sodium | 16 | $1,354 |
| Tizanidine Hcl | 100 | $1,214 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 117 | $1,206 |
| Celecoxib | 20 | $1,168 |
| Oxycodone Hcl | 166 | $1,098 |
| Meloxicam | 561 | $1,034 |
| Diclofenac Sodium | 31 | $981 |
| Lidocaine | 19 | $934 |
| Doxycycline Hyclate | 89 | $749 |
| Duloxetine Hcl | 12 | $348 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 38 | $335 |
| Ketoconazole | 33 | $318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $50 | $8,51716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 163 foot and ankle surgery providers in Missouri.
Other foot and ankle surgery in Lees Summit
- Raquel SuginoLees Summit$77K
- David MillwardLees Summit$61K
- Raymond RizziLees Summit$27K
- Alan ZonnoLees Summit$20K
- Elliott WitykLees Summit$12K
- Jeremy McCormickSaint Louis$1.5M
- Jeffrey JohnsonSaint Louis$944K
- Timothy BadweyKansas City$427K
- Raymond AbdoSaint Louis$251K
- Vincent SollecitoSaint Louis$221K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.